title: Identification of human platelet glycoprotein VI-specific IgG autoantibody and its fragments.
abstract: Glycoprotein VI (GPVI), as a major receptor for collagen on the platelet surface, mediates the initial platelet contact with collagen, and causes platelet aggregation and thrombosis. Agents of anti-GPVI can inhibit the adhesion, activation and aggregation function of platelets, which can be used for preventing thrombotic diseases. To make humanized monoclonal antibodies by phage surface display technology, we studied plasmas from 44 patients with chronic idiopathic thrombocytopenic purpura using modified monoclonal antibody immobilization of platelet antigen assays. GPVI-specific antibodies were found in six (13.6%) patients. Among these, only one showed significant inhibition of platelet aggregation induced by collagen. The IgG antibody and F(ab')2 fragments of this patient's plasma were further purified and their immunoreactivities and effects on platelet aggregation were reanalyzed. It was found that purified IgG and its F(ab')2 fragments from the patient not only retained the ability to bind to platelet GPVI, but also inhibited collagen-induced platelet aggregation. In this study, therefore, the specific anti-platelet GPVI autoantibody that inhibits collagen-induced platelet aggregation has been successfully screened out, which can be used to develop completely humanized anti-GPVI phage antibody.
authors.affiliation: Hematology Oncology Center, Qilu Hospital of Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Chu
authors.forename: Ming
authors.initials: M
authors.lastname: Hou
authors.forename: Jun
authors.initials: J
authors.lastname: Peng
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhu
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Xuebin
authors.initials: X
authors.lastname: Ji
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Daoxin
authors.initials: D
authors.lastname: Ma
mesh_terms: D000077284:Abciximab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001323:Autoantibodies / Q000097:blood* / Q000737:chemistry; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000097:blood* / Q000494:pharmacology; D007074:Immunoglobulin G / Q000097:blood* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010980:Platelet Membrane Glycoproteins; C098341:platelet membrane glycoprotein VI; D000077284:Abciximab